Optinose plans to raise funds through an initial public offering of 2.25 million shares of its common stock.
The underwriters will receive a 30-day option to buy an additional 675,000 shares.
Based in the US, Optinose is a pharmaceutical company focused on the development of innovative products for patients with ear, nose and throat (ENT) allergies.
The funds are intended to be used towards the commercialisation and further development of its XHANCE nasal spray indicated for the treatment of nasal polyps. The funds will also be used for working capital and other general corporate purposes.
Kitov Pharma has signed an agreement to raise $8.15m through a private placement of 3.26 million American Depositary Shares (ADS) priced at $2.50 per ADS.
The warrants will be exercisable at a price of $2.8 per ADS and have a term of 5.5 years.
Based in Israel, Kitov is a biopharmaceutical company focused on end-to-end drug development.
Clovis Oncology and Immunomedics have collaborated to investigate the combination of the former’s poly polymerase inhibitor Rubraca with the latter’s lead product candidate sacituzumab govitecan for the treatment of patients with metastatic triple-negative breast cancer (mTNBC) and metastatic urothelial cancer (mUC).
Based in the US, Clovis is a manufacturer of anti-cancer agents, while Immunomedics, also based in the US, is a biopharmaceutical company that provides novel immuno-therapeutics for the treatment of cancer and other serious diseases.
The collaboration enables the two companies to develop treatments for advanced breast and bladder cancers.
Bayer plans to raise €6bn ($7bn) through a rights offering of shares of its common stock.
Bayer simultaneously plans to raise €20bn ($23.31bn) through the issuance of bonds in a private placement.
The company plans to use the funds to support the proposed acquisition of Monsanto, an American agrochemical and agricultural biotechnology corporation.
Based in Germany, Bayer is a life science, chemical and pharmaceutical company.
Merrill Lynch, Pierce, Fenner & Smith and Credit Suisse Group were appointed as underwriters to Bayer for the offering.
Upsher-Smith Laboratories has signed a marketing and distribution agreement with an undisclosed pharmaceutical company for six ophthalmic and otic ANDA products.
Upsher-Smith will register the six products with the US Food and Drug Administration (FDA) and market them under its own brand in the US, post approval. The undisclosed pharmaceutical company will develop and produce the products solely for Upsher-Smith.
Based in the US, Upsher-Smith is a provider of high-quality pharmaceutical products.
The partnership enables Upsher-Smith to significantly expand its product pipeline.